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Abstract Pancreatic phospholipase A2 (PLA2-I) stimulates UIII
cells proliferation, a rat uterine cell line, after binding to
membrane receptors, internalization and translocation. Here, we
demonstrate that during these steps of internalization, PLA2-I
retains its hydrolytic activity and thus could exert its prolif-
erative effect via nuclear phospholipids hydrolysis. Since fatty
acids and eicosanoids released by such activity are known to be
ligands of PPAR, we study the expression of these nuclear
receptors and demonstrate that, in the experimental conditions
where PLA2-I stimulates UIII cells proliferation, PLA2-I also
regulates PPAR expression indicating a possible mechanism of
its proliferative effect. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Phospholipases A2 (PLA2) are implicated in a great diver-
sity of cell functions and particularly they play a crucial role
in signal transduction [1]. These lipolytic enzymes (EC 3.1.1.4)
of which di¡erent forms have been described in various tis-
sues, hydrolyze the sn-2 acyl ester bond in glycerophospho-
lipids. They are traditionally classi¢ed according to their pri-
mary structure and their sensitivity towards intracellular
concentrations of calcium [2]. The calcium-dependent enzymes
have been subdivided into two main groups. The secretory
forms (sPLA2) are low molecular mass (13^18 kDa), extracel-
lular secreted enzymes acting at millimolar concentrations of
calcium, including pancreatic and Naja venom PLA2 (type I),
Crotalus venom and in£ammatory PLA2 (type II), bee venom
PLA2 (type III), and the PLA2 recently identi¢ed in the heart
and the lung (type V) [3]. On the other hand, intracellular
cytosolic PLA2 (cPLA2) constitutes the high molecular mass
(85 kDa) type IV group of molecules sensitive to micromolar
concentrations of calcium [4]. The calcium-independent
PLA2s (iPLA2) with molecular mass varying in the range of
29^120 kDa have recently been described in a variety of tis-
sues [5]. In almost every cell studied, multiple PLA2s exist but
their relative contribution to the cell function is not yet under-
stood.
The pancreatic type PLA2-I, which has long been thought
to act only as a digestive enzyme, has been shown to stimulate
cell proliferation via a speci¢c membrane receptor [6]. Cloning
of PLA2 receptors from several species has revealed a struc-
tural organization of the protein which is highly similar to
that of mannose receptors [7]. It has been proposed that the
physiological role of this PLA2 receptor is to internalize and
deliver PLA2-I to speci¢c intracellular compartments where
the enzyme can exert its activity [8].
We have recently demonstrated that nanomolar concentra-
tions of pancreatic PLA2 stimulate the proliferation of UIII
cells, a stromal cell line (UIII) derived from normal rat uterus
[9,10]. Analysis of cellular uptake of exogenous PLA2-I by
UIII cells in culture revealed the presence of membrane recep-
tors for PLA2-I, which were responsible for internalization of
the ligand [11]. The number of PLA2 receptors is closely as-
sociated with the proliferative state of UIII cells [10]. More-
over, subsequent studies showed that the internalized enzyme
migrates to the nucleus, suggesting that the proliferative e¡ect
of pancreatic PLA2 in UIII cells is mediated by a direct action
of the enzyme at the nuclear level [12]. To investigate whether
PLA2-I has retained its hydrolytic activity during the steps of
internalization and nuclear migration, we studied PLA2 activ-
ity in puri¢ed nuclear preparations and we demonstrated that,
after translocation into the nucleus, the PLA2-I was still able
to hydrolyze phospholipids. The hydrolytic activity of PLA2-I
could lead to the release of fatty acids and production of
eicosanoids at the nuclear level. Since these products have
been shown to stimulate peroxisome proliferator-activated re-
ceptors (PPARs) [13] and in order to get further information
on the mechanism of action of the enzyme at the nuclear level,
we also studied the PPAR expression in UIII cells. Our results
indicate that the proliferative e¡ect of PLA2-I may be medi-
ated by di¡erential regulation of PPAR-K and -Q expression.
2. Materials and methods
2.1. Cell culture
For stock culture, rat uterine stromal cells (UIII cells) were grown in
Falcon plastic £asks (75 cm2) in a 95% air^5% CO2 humidi¢ed atmos-
phere at 37‡C. The medium was M199 supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 Wg/ml
streptomycin. Medium was changed every 48 h. Con£uent cells were
subcultured by incubation with 0.25% trypsin, centrifuged and seeded
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at 1:2 ratio. Cell viability, determined by the trypan blue exclusion
method, was consistently greater than 95%.
2.2. Isolation of nuclei
Procedures of cell homogenization using ionic salt solutions were
avoided since they often induce artefactual transfer of molecules from
the nuclear compartment to the cytoplasm. Nuclei were prepared ac-
cording to the method of Nicotera and al. [14] with some modi¢ca-
tions. UIII cells from subcon£uent stock cultures were trypsinized and
centrifuged at 800Ug for 5 min. The pellet was rinsed twice with
phosphate-bu¡ered saline and resuspended into three volumes of
TKM solution (50 mM Tris^HCl, pH 7.5, 25 mM KCl, 5 mM MgCl2,
2 Wg/ml leupeptin and pepstatin with 0.1% Triton X-100) supple-
mented with 0.25 M sucrose, brie£y sonicated using a microprobe
and centrifuged again at 700Ug for 10 min at 4‡C. The resulting
pellet was resuspended into two volumes of the above TKM^0.25
M sucrose solution, then one volume of sample was gently mixed
with two volumes of TKM supplemented with 2.3 M sucrose.
TKM^2.3 M sucrose (one volume) was placed into centrifuge tubes
(ultraclear no. 344057, Beckman) and two volumes of experimental
sample were layered on the top. The tube was centrifuged at 37 000Ug
for 45 min at 4‡C. The supernatant was discarded and the nuclei pellet
was resuspended in TKM solution and pelleted at 1000Ug for 5 min
at 4‡C. The ¢nal pellet was resuspended into 50 mM Tris^HCl, pH
7.5 and analyzed. DNA content of the sample was determined on an
aliquot by a £uorometric procedure as described previously [15]. The
purity of the nuclear preparations was analyzed by measuring 5P-nu-
cleotidase and glucose 6-phosphatase activities. In all experiments,
these enzymatic activities in nuclear fractions were less than 2% of
that observed in the cellular homogenate indicating the almost com-
plete absence of contamination by plasma membrane and by micro-
somes. The yield of extractions, determined by measuring DNA
amount in nuclear and in cell homogenates, was 15.3 þ 1.4% for 10
independent extractions (mean þ S.E.M.). Some experiments were
done to increase this yield, but this was detrimental for the purity
of nuclear preparation.
2.3. PLA2 activity measurement
Secreted PLA2 activity in the nuclear preparations was determined
by using a £uorometric method derived from the technique of Rad-
vanyi and al. [16]. For PLA2 activity measurement, 100 Wl of 2 mM
PG substrate (1-hexadecanoyl-2-(10-pyrenedecanoyl)-sn-glycero-3-
phosphoglycerol, ammonium, Interchim, Montluc°on, France) stored
at 380‡C in toluene-isopropanol (50/50 v/v) was evaporated under
nitrogen and dissolved in 1 ml ethanol. 100 Wl of this solution was
mixed with 10 ml of 50 mM Tris^HCl bu¡er, 100 mM NaCl, 1 mM
EGTA, pH 7.5, vortexed for 2 min and maintained at room temper-
ature.
Incubation medium was prepared in a £uorometric cuve by adding
successively 1940 Wl of the PG substrate (2 WM ¢nal concentration)
and 20 Wl of fatty acid free bovine serum albumin (BSA) solution
(0.1% ¢nal concentration). 10^50 Wl aliquots of nuclei kept at 0‡C
were added and equilibrated at room temperature for 1 min. The
reaction started by adding 20 Wl of 1 M CaCl2 and £uorescence was
measured continuously with a spectro£uorometer Jobin Yvon JY3D.
Secreted PLA2 activity was estimated by measuring the slope of the
curve and expressed as nmol of substrate hydrolyzed/min/mg DNA.
E¡ect of antibodies against PLA2 on the nuclear PLA2 activity was
measured after preincubation for 12 h at 4‡C with a polyclonal anti-
body produced in our laboratory [17] and puri¢ed on a DEA chro-
matography column [18]. These antibodies are speci¢c for PLA2-I and
inhibit the binding of the enzyme to its receptor [17].
2.4. Fluorescence microscopy
For immuno£uorescence studies, cells were seeded (5U104 cells per
well) and cultured in 4-well plastic culture dishes as previously de-
scribed [12]. Brie£y, staining was performed by incubating cells over-
night at 4‡C with polyclonal antibodies against the whole PPARs [20],
PPAR-K and PPAR-Q2 (a subtype of PPAR-Q di¡ering by add of 30
amino acids in N-terminal domain to the PPAR-Q1) [19] (dilution
1/20). The staining was followed by four washes with HBSS^1%
BSA. The cells were then exposed for 30 min at 4‡C to the secondary
£uorescent TRITC-conjugated antibody in HBSS^1% BSA (dilution
1/20) and washed four times in the same solution without the anti-
body. The cell preparations were analyzed using a £uorescence micro-
scope (Leitz Laborlux).
2.5. Statistical analysis
Data are expressed as the mean þ S.E.M. Statistical signi¢cance
(O= 0.05) was tested using Mann^Whitney or Kruskal^Wallis non-
parametric rank tests [21].
3. Results and discussion
UIII cells express speci¢c membrane receptors for PLA2-I
which undergo cycles of binding, intracellular transfer and
release of the enzyme [11]. The internalized enzyme then mi-
grates to the nucleus [12]. The number of receptors and thus
the capacity of the cells to internalize PLA2-I decrease when
cells progress from a non-con£uent proliferating state to a
con£uent contact inhibited monolayer [10]. Consequently,
the intracellular concentration of PLA2-I is signi¢cantly re-
duced, about 3-fold, in con£uent cells. This reduction a¡ects
almost exclusively the nuclear content of the enzyme which is
much more concentrated in the nuclear fraction of non-con-
£uent cells [12]. To investigate whether the PLA2-I located in
the nuclear compartment still expresses its hydrolytic activity,
con£uent and non-con£uent cells were incubated for 48 h with
or without 30 nM porcine pancreatic PLA2. At the end of
incubation, cells were washed several times and nuclei were
prepared. Secreted PLA2 activity was measured in the di¡er-
ent nuclear preparations. In the absence of calcium, no detect-
able PLA2 activity was observed in the nuclear samples ana-
lyzed. In the presence of calcium, a signi¢cant enzyme activity
was measured in all samples and the results are summarized in
Fig. 1. Enzyme activity was greater (3.1-fold) in nuclei from
non-con£uent cells (NC3) compared to nuclei from con£uent
cells (C3). Moreover, when non-con£uent cells were incu-
bated with 30 nM porcine pancreatic PLA2-I for 48 h, nuclear
enzyme activity was increased by more than 5-fold (NC+
versus NC3). When con£uent cells were preincubated with
exogenous PLA2-I, nuclear enzyme activity was also increased
Fig. 1. PLA2 activity in nuclear preparations from con£uent and
non-con£uent cells. Con£uent cells (C) or non-con£uent cells (NC)
were incubated for 48 h without (3) or with 30 nM of PLA2-I (+).
The PLA2 activities, expressed as nmol of hydrolyzed substrate per
minute and per mg of DNA, are means þ S.E.M. of six and 18 inde-
pendent measures for con£uent and non-con£uent cells, respectively.
*Signi¢cantly di¡erent from control C3, P6 0.05. ‡Signi¢cantly dif-
ferent from control NC3, P6 0.05.
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but less than in non-con£uent cells (about 3-fold). When non-
con£uent cells were incubated for 48 h with 30 nM Naja naja
mocambique venom PLA2 (type I PLA2) or Crotalus atrox
venom PLA2 (type II PLA2), two secreted PLA2s showing a
much lower a⁄nity for UIII cell PLA2 binding sites than the
pancreatic enzyme [11], no increase in nuclear enzyme activity
was observed (Fig. 2).
Taken together, these results strongly suggest that PLA2-I
retains its hydrolytic activity during the steps of binding, in-
ternalization and nuclear migration. In rat mesangial cells,
PLA2-I was shown to stimulate prostaglandin biosynthesis
by induction of PLA2-II expression via a speci¢c binding
site [22]. PLA2-I was also shown to release arachidonic acid
from NIH 3T3 cells via a receptor-mediated mechanism [23].
The authors suggested that PLA2-I may induce the expression
of a Ca2-independent PLA2 that in turn mediates arachidon-
ic acid release. In order to be sure that the increase in nuclear
enzyme activity, observed after incubation of cells with pan-
creatic PLA2, resulted from the accumulation of the exoge-
nous enzyme in an active form in the nuclear compartment,
the non-con£uent cells, preincubated with 30 nM pancreatic
PLA2, were incubated with increasing amounts of anti-PLA2-I
antibodies before measurement of enzyme activity. Results
(Fig. 3) show a dose-dependent decrease of enzyme activity
while non-immune immunoglobulins were without e¡ect,
demonstrating the presence of active PLA2-I in UIII cells nu-
clei and that the increasing enzyme activity was not the result
of the expression of another PLA2. Moreover the hydrolytic
activity of nuclei isolated from control non-con£uent cells was
completely abolished by the incubation with the anti-PLA2-I
antibodies. This result suggests that the PLA2-I is the only
secreted PLA2 present and/or active in the nuclear compart-
ment. As PLA2-II has already been detected in UIII cells [12],
this means that it is either absent or inactive in the nucleus.
The presence of lipids inside the nucleus that could be po-
tential substrates for PLA2 was reported long ago [24,25] but
has not received much attention. Initially considered as struc-
tural elements [26] these nuclear phospholipids may also be
involved in the control of genomic activities as suggested by
their higher concentration in active chromatin [27]. Cell cycle-
dependent changes in synthesis rates of the chromatin-associ-
ated pools of phospholipids have been reported [28] and
changes in fatty acid composition of nuclear phospholipids
have also been described during liver regeneration [29]. This
suggests a direct involvement of nuclear matrix lipids in cell
proliferation. On the other hand, fatty acids are now consid-
ered as intracellular second messengers which can be involved
in the regulation of cell growth by a direct genomic action
[30]. An arachidonic acid response element has recently been
identi¢ed [31]. Numerous data have also shown that fatty
acids are able to directly interact with nuclear receptors and
regulate transcription, sharing true properties of hormones
[32]. In particular, long chain fatty acids and eicosanoids
have been described as ligands for nuclear PPARs [13].
PPARs are members of the well-known steroid receptor super
family, three subtypes have been identi¢ed and cloned:
PPAR-K, -L and -Q (the latter exists as two isoforms, Q1 and
Q2) and a well documented literature has recently been pub-
lished about their tissue distribution and functions [32,33].
Taking into account all these data, a working hypothesis
for the mechanism of action of PLA2-I in UIII cells could be
that the enzyme hydrolyzes nuclear phospholipids leading to
the generation of speci¢c ligands for PPAR and resulting in
Fig. 2. E¡ect of various exogenous secreted PLA2s on PLA2 activity
of nuclear preparations. Non-con£uent cells were incubated during
48 h without (controls) or with 30 nM of pancreatic PLA2-I, Crota-
lus PLA2-II or Naja PLA2-I. The PLA2 activities, expressed as
nmol of hydrolyzed substrate per minute and per mg of DNA, are
means þ S.E.M. of four independent measures. *Signi¢cantly di¡er-
ent of controls, P6 0.05.
Fig. 3. Inhibition of nuclear PLA2 activity by antibodies against
PLA2-I. Nuclear preparations, obtained from cells preincubated dur-
ing 48 h without (3) or with 30 nM PLA2-I (+), were incubated
overnight without (C) or with 45 nM (Ab 1), 67 nM (Ab 2), 90 nM
(Ab 3) of anti-PLA2-I antibodies or with 90 nM of rabbit IgG
(IgG). The PLA2 activities, expressed as nmol of hydrolyzed sub-
strate per minute and per mg of DNA, are means þ S.E.M. of two
independent measures. ‡Signi¢cantly di¡erent from control C3,
P6 0.05. *Signi¢cantly di¡erent from control C+, P6 0.05.
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transcriptional activation of gene expression. In order to test
this hypothesis, we ¢rst investigated the expression of PPAR
in non-con£uent cells incubated in the presence or absence of
30 nM pancreatic PLA2. Data presented in Fig. 4 show that
UIII cells express PPAR-K and -Q2 in a constitutive manner.
When UIII cells were preincubated for 2 h with exogenous
PLA2-I, the whole PPAR expression was enhanced (Fig. 4d
versus Fig. 4c).
However a di¡erential regulation of PPAR-K and PPAR-Q2
expression was apparent since the expression of PPAR-K was
reduced in cells preincubated with the exogenous enzyme (Fig.
4f versus Fig. 4e) while that of PPAR-Q2 was greatly increased
(Fig. 4h versus Fig. 4g). The presence of PPAR-K in UIII cells
is in accordance with its ubiquitous pattern of expression and
its presence in the rat uterus as has already been described
[20]. The inhibitory e¡ect of PLA2 on PPAR-K expression is
also in accordance with a number of data showing that glu-
cocorticoids, which are well-known to inhibit the secreted
form of PLA2 [34], also activate PPAR-K expression [32].
Since PPAR-Q expression is more restricted, the presence of
PPAR-Q2 in UIII cells and the induction of its expression by
PLA2-I seems to be of great interest. Although, PPAR-Q is
generally considered as a key transcription factor involved in
adipocyte di¡erentiation [33,35,36]. It has also been described
in non-adipose tissues such as the spleen, mucosa of duode-
num and retina [37], indicating that PPAR-Q is probably more
widely distributed than it was initially considered. Interest-
ingly, recent evidence has been demonstrated that PPAR-Q is
highly expressed in colon and breast cancer cells [38,39]. The
PLA2-I-induced PPAR-Q2 expression in UIII cells leads us to
attribute a more general function to PPAR-Q2 in controlling
cell behavior for di¡erentiation or proliferation. Then, the
proliferative e¡ect of the PLA2-I on UIII cells could be ex-
erced, after binding to its membrane receptor, internalizing
and migrating toward the nucleus, via PPAR-Q2 and peroxi-
somes. Thus, we can suggest, like it was soon demonstrated in
bacteria [40], that the proliferation in eukaryotes could also be
induced by molecular hyperstructure associating DNA, pro-
teins and lipids.
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